Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Caraco agrees to undertake action to get USFDA ban lifted
Sun Pharma"s US-based subsidiary Caraco Pharmaceuticals has agreed to undertake a series of measures as per requirements of the US health regulator Food and Drug Administration (FDA) to get a ban on its manufacturing units lifted.

NIIT Tech patners Hitachi for cloud computing
NIIT technologies has announced partnership with Hitachi Information Systems to offer cloud computing services. Cloud computing is an emerging mega trrend which is standardized IT capability delivered via the internet in a pay per use and self service manner. With cloud computing gaining impetus, both companies will be able to offer the complete portfolio of services around the cloud infrastructure to cater to the changing IT landscape.

News of the day

India's moon mission quite economical
India"s moon mission has proved to be quite economical and cost much less compared to what other countries have spent on their projects, mission director M Annadurai said here.
Small Business

Cadila Pharma eyes Rs 80 crore from Risorine

Aims to enter China, Russia and African countries - Cadila-Novavax JV can produce 250 mn doses of H1N1 vaccine - Cadila Pharma-Novavax JV to produce swine flu vaccine - Cadila expects Rs 100-cr revenue from Policap - Cadila looking at global tie-ups for Polycap - Cadila Pharma to launch product to curb sudden cardiac death Ahmedabad-based pharma major Cadila Pharmaceuticals is betting big on the latest product from its stable, Risorine, a combination drug for treating tuberculosis, as it plans to take the drug to markets like China, Russia and African countries in the long run and also expects to multiply its turnover from the segment by over ten times in the coming two years. Speaking at the launch of the drug, I A Modi, chairman, Cadila Pharmaceuticals said that he expected the company"s revenues from the tuberculosis segment which is around Rs 6-8 crore now to touch over Rs 80 crore within the next two years. "Currently, the share of tuberculosis department of respiratory medicine at NHL Municipal Medical College at Ahmedabad, pointed out that Risorine could even replace the currently used Rifampicin used in the "Directly Observed Treatment Short-course" (DOTS) therapy. Nearly, 70-80 per cent of all tuberculosis cases in the country would receive medication under the DOTS programme run by the Central government in association with states.” "Even out of these patients, nearly 50 per cent do come to a private practitioner for advice", observed Naresh Patel, faculty and head, Tuberculosis and Respiratory Medicine, NHL, Municipal Medical College, Ahmedabad. India currently houses the maximum number of tuberculosis patients in the world, nearly 21 per cent of the world"s patient population. The country reports two deaths in every three minutes. On top of this, India has more than 25 lakh HIV positive cases and the risk of contracting tuberculosis is around five times more in these patients.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009